Publications

Wale, A. Bernier, L. Tait, D. Rao, S. Brown, G. (2024). Simple imaging biomarker predicts survival in anal squamous cell cancer treated with curative intent: a UK cohort study. Clin radiol, Vol.80, p. 106718. show abstract

Hallemeier, C.L. Huguet, F. Tait, D. Buckstein, M.H. Anker, C.J. Kharofa, J. Olsen, J.R. Jabbour, S.K. (2021). Randomized Trials for Esophageal, Liver, Pancreas, and Rectal Cancers. Int j radiat oncol biol phys, Vol.109 (2), pp. 305-311.

Brooks, C.J. Bernier, L. Hansen, V.N. Tait, D.M. (2018). Target volume motion during anal cancer image guided radiotherapy using cone-beam computed tomography. Br j radiol, Vol.91 (1085), p. 20170654. show abstract full text

Bhoday, J. Glimelius, B. Tait, D. Glynne-Jones, R. Adams, R. Brown, G. (2018). Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. Colorectal dis, Vol.20 Suppl 1, pp. 97-99. show abstract

Dattani, M. Marijnen, C. Moran, B. Tait, D. Cunningham, C. Rodriguez-Bigas, M. Brown, G. (2018). Session 4: Shaping radiotherapy for rectal cancer: should this be personalized?. Colorectal dis, Vol.20 Suppl 1, pp. 92-96. show abstract

Bernier, L. Balyasnikova, S. Tait, D. Brown, G. (2018). Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. Curr colorectal cancer rep, Vol.14 (2), pp. 37-55. show abstract full text

De Francesco, I. Thomas, K. Wedlake, L. Tait, D. (2016). Intensity-modulated Radiotherapy and Anal Cancer: Clinical Outcome and Late Toxicity Assessment. Clin oncol (r coll radiol), Vol.28 (9), pp. 604-610. show abstract

AIMS: To assess the potential impact on long-term consequences of treatment (intensity-modulated radiotherapy with concomitant chemotherapy) in patients diagnosed with anal cancer. MATERIALS AND METHODS: We identified 43 eligible patients treated with concomitant chemoradiotherapy (pelvic intensity-modulated radiotherapy) at the Royal Marsden Hospital between 2010 and 2013. We determined late genitalia and bowel side-effects using specific questionnaires [Pelvic Symptom Questionnaire, Vaizey Incontinence Questionnaire, Inflammatory Bowel Disease Questionnaire (IBDQ) and IBDQ-B]. Using descriptive statistics, we report clinical outcomes in all patients, by time, since the end of treatment (grouped as 1-1.5, 1.5-2.5 and 2.5-3.5 years). RESULTS: Twenty-seven of 43 (63%) patients were identified as available for questionnaire follow-up. Reasons for unavailability were death (n = 3), lost to palliative care service (n = 1), referred to surgery (n = 4), lost to follow-up (n = 8). In the 27 patients studied, bowel toxicity was assessed by IBDQ, IBDQ-B and the Vaizey Incontinence Questionnaire. The median value was 208 for IBDQ, 38 for IBDQ-B and 3.0 for the Vaizey Incontinence Questionnaire, as assessed at 1 year or more post-completion of treatment. Treatment was reported to affect quality of life/sexual function in two of the female patients (n = 21) and three male patients (n = 6). No insufficiency fractures have been reported. Bone marrow function remained stable over the time of the follow-up. CONCLUSIONS: Although there are data supporting a reduction in acute effects using intensity-modulated radiotherapy in anal cancer, there is very little in the literature to establish the late toxicity profile. Our results indicate that there is an effect on bowel and sexual function, but it does not increase over the period observed. These data provide a benchmark against which to compare outcomes with future manipulation in treatment, and provide us with real information to give patients as to the expectation of their functional outcome after treatment..

Edmunds, K. Brooks, C. Hansen, V.N. Harris, V. Tait, D.M. (2015). Cardiac volume effects during chemoradiotherapy for esophageal cancer (Regarding Lutkenhaus et al Reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer). Radiother oncol, Vol.114 (1), pp. 128-129.

De Francesco, I. Thomas, K. Tait, D.M. (2015). Pelvic Intensity-modulated Radiotherapy: Can we Better Quantify the Late Side-effects?. Clin oncol (r coll radiol), Vol.27 (7), p. 428.

Brooks, C. Hansen, V.N. Riddell, A. Harris, V.A. Tait, D.M. (2015). Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy. Br j radiol, Vol.88 (1051), p. 20150032. show abstract full text

Hafeez, S. Bedford, J.L. Tait, D.M. Hawkins, M.A. (2014). Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours. Acta oncol, Vol.53 (1), pp. 149-154.

Tait, D. (2014). Radiation therapy in the United Kingdom and the wider role of the clinical oncologist. Int j radiat oncol biol phys, Vol.89 (1), pp. 1-3.

Yu, S.K. Bhangu, A. Tait, D.M. Tekkis, P. Wotherspoon, A. Brown, G. (2014). Chemoradiotherapy response in recurrent rectal cancer. Cancer med, Vol.3 (1), pp. 111-117. show abstract

Beyond, TME, Collaborative, Corporate, Authors, Tait, D. (2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br j surg, Vol.8 (100), pp. 1009-6.

Hoskins, P.J. Forbes, H. Ball, C. Riley, D. Cooper, T. Tait, D. (2013). Variations in Radiotherapy Delivery in England - Evidence from the National Radiotherapy Dataset. Clinical oncology, Vol.25 (9), pp. 531-6.

Schiavon, G. Tait, D.M. Briggs, T.W. Smith, I.E. (2013). A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines. Clin breast cancer, Vol.13 (1), pp. 77-80.

Brooks, C.J. Lee, Y.K. Aitken, K. Hansen, V.N. Tait, D.M. Hawkins, M.A. (2013). Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin oncol (r coll radiol), Vol.25 (3), pp. 155-161. show abstract

Wedlake, L.J. Silia, F. Benton, B. Lalji, A. Blake, P. Tait, D. Khoo, V.S. Andreyev, H.J. (2013). Letter in response to Dearnaley et al letter regarding paper: Evaluating the efficacy of statins and angiotensin converting enzyme-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur j cancer, Vol.49 (7), pp. 1781-1782.

Hawkins, M.A. Bedford, J.L. Warrington, A.P. Tait, D.M. (2012). Volumetric modulated arc therapy planning for distal oesophageal malignancies. Br j radiol, Vol.85 (1009), pp. 44-52. show abstract full text

Alfa-Wali, M. Allen-Mersh, T. Antoniou, A. Tait, D. Newsom-Davis, T. Gazzard, B. Nelson, M. Bower, M. (2012). Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann oncol, Vol.23 (1), pp. 141-147. show abstract

Yu, S.K. Brown, G. Tait, D.M. (2012). Use of MRI-defined tumor distance from the anal verge to predict tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. J clin oncol, Vol.30 (4_suppl), p. 573. show abstract

573 Background: Neoadjuvant Chemoradiotherapy (CRT) and surgical resection is the current standard management for patients with locally advanced rectal cancer (i.e. T3 or 4 N0/1 M0) (LARC). Tumour predictive factors for response to CRT in rectal cancer remain controversial. Staging investigations are not standardised and MRI has not been used consistently to approach this. The aim of this study is to investigate whether tumour distance from anal verge, as measured on MRI, is a predictive factor for response to CRT in LARC. METHODS: This is a retrospective study. Patients with LARC or low T2 N0/1 M0 rectal cancer (i.e. ≤ 5cm from anal verge measured by MRI) treated with preoperative CRT in 2003- 2009 were included. Pelvic MRIs acquired before CRT and no less than 4 weeks post CRT were reviewed. Patients with ypT0-2 in the resected specimen were classified as responders because ypT0-2 has been shown with significant OS and DFS benefit (Valentini V et al. Int J Radiat Oncol Biol Phys. 2002; 53(3): 664-74). Downstage of mrT2 low rectal cancer was defined as ypT0-1 post CRT. Univariate binary logistic regression (UBLR) was used to analyse the predictor associated between responders and non-responders to CRT treated in the same period of time. RESULTS: 281 patients with LARC who underwent CRT were included in the study. 96% patients in this study had T3/T4 LARC and 4% had T2 low rectal cancer. 114 (41%) were responders as defined above, 167 (59%) were non-responders to CRT. The mean MRI defined tumour distance from anal verge was significantly less in responders (6.4cm [Confidence Intervals (CI) = 5.7 -7.1]) when compared with non-responders (7.9cm [CI =7.3 - 8.6]) (P<0.05). CONCLUSIONS: The UBLR analysis from our study indicated that an MRI measured tumour distance of ≤ 5cm from the anal verge independently predicted higher tumour downstaging rate (p < 0.001) to CRT in LARC. Further investigation is recommended regarding tumour downstaging and sphincter preserving surgical resection rate in low rectal cancer post neoadjuvant CRT. [Table: see text]..

Wedlake, L.J. McGough, C. Shaw, C. Klopper, T. Thomas, K. Lalji, A. Dearnaley, D.P. Blake, P. Tait, D. Khoo, V.S. Andreyev, H.J. (2012). Clinical trial: Efficacy of a low or modified fat diet for the prevention of gastrointestinal toxicity in patients receiving radiotherapy treatment for pelvic malignancies. J hum nutr diet, Vol.25 (3), pp. 247-259. show abstract

Tuan, J. Ha, T.C. Chen, W. Hawkins, M. Tait, D. (2012). Effect of Anaemia Prevention on Survival and Local Control in Oesophageal Cancers Treated with Chemoradiotherapy. Clinical oncology, Vol.24 (6), pp. 454-455.

Wedlake, L.J. Silia, F. Benton, B. Lalji, A. Thomas, K. Dearnaley, D.P. Blake, P. Tait, D. Khoo, V.S. Andreyev, H.J. (2012). Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur j cancer, Vol.48 (14), pp. 2117-2124. show abstract

Dewdney, A. Cunningham, D. Tabernero, J. Capdevila, J. Glimelius, B. Cervantes, A. Tait, D. Brown, G. Wotherspoon, A. Gonzalez de Castro, D. Chua, Y.J. Wong, R. Barbachano, Y. Oates, J. Chau, I. (2012). Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J clin oncol, Vol.30 (14), pp. 1620-1627. show abstract

Yu, S.K. Brown, G. Heald, R.J. Chua, S. Cook, G. Barbachano, Y. Chau, I. Wotherspoon, A. Tait, D.M. (2011). Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom. J clin oncol, Vol.29 (4_suppl), p. 489. show abstract

489 Background: Neoadjuvant chemoradiotherapy (CRT) and surgical resection are standard components of therapy for patients locally advanced rectal cancer (T3,T4 or N+) in UK. In 15%-30% of patients treated pre-operatively with CRT will develop pathological complete response (CR). The time from completion of CRT to maximal tumour response is as yet unknown. This study is the first prospective study to attempt to identify the percentage of patients who can safely omit surgery and the safety of deferred surgery in patients who achieve clinical complete response post CRT. Of the 59 patients required for the study, this provides an update on 19 patients entered. METHODS: Patients with locally advanced rectal cancer requiring neoadjuvant treatment are identified in the multidisciplinary meet (MDT). Patients undergo CRT using a minimum of 50.4Gy in 28 # daily conformal CT planned CRT with concomitant Capecitabine at 825mg/m(2) BD. MRI pelvis and body CT are repeated 4 weeks post CRT and rediscussed at MDT. If there is a good partial response or CR, patients are considered for Deferral of Surgery Study. Based on the pre treatment clinical staging, patients are considered for adjuvant chemotherapy as per NICE guidance. At any point of the study, if there is histology proven tumour regrowth or progression, patient undergo surgery. RESULTS: 10 (53%) patients remain in CR. 6 (32%) patients underwent surgical resection with clear margin after detection of tumour regrowth at from 2-23 months post CRT. 5 out of 6 of the patients with tumour regrowth underwent PET CT as per protocol, and all tumour regrowth in those 5 patients were detected by PET CT, i.e. FDG avid disease. The pathological stages on these 6 patients were ypT2N0 CRM negative in 5 and ypT3N0 CRM negative in 1. 3 (15%) patients with tumour regrowth refused surgery. CONCLUSIONS: In the 19 recruited patients, all the patients with tumour regrowth underwent surgical resection with clear margins. PET CT appears a useful tool for detecting tumour regrowth. The median time for tumour regrowth is 17.5 months post CRT. The trial will be successful if at least 11/59 patients are able to safely omit surgery. Accrual of patients continues. No significant financial relationships to disclose..

Hawkins, M.A. Aitken, A. Hansen, V.N. McNair, H.A. Tait, D.M. (2011). Set-up errors in radiotherapy for oesophageal cancers--is electronic portal imaging or conebeam more accurate?. Radiother oncol, Vol.98 (2), pp. 249-254. show abstract

Brooks, C.J. Lee, Y.K. Aitken, K. Hansen, V.N. Tait, D.M. Hawkins, M.A. (2011). Organ Sparing IMRT for Anal Cancer using ACTII Schedule: a Comparison of Conventional and IMRT Plans. Clinical oncology, Vol.23 (3), pp. S31-S31.

Alfa-Wali, M. Allen-Mersh, T. Antoniou, A. Tait, D. Newsom-Davis, T. Gazzard, B. Nelson, M. Bower, M. (2011). Chemoradiotherapy of anal cancer in HIV patients causes prolonged CD4 cell count suppression. Hiv medicine, Vol.12, pp. 7-7.

Hawkes, E.A. Cunningham, D. Tait, D. Brown, G. Chau, I. (2011). Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm?. Semin radiat oncol, Vol.21 (3), pp. 196-202. show abstract

Gujral, D.M. Hawkins, M.A. Leonulli, B.G. Ashley, S. Chau, I. Cunningham, D. Tait, D. (2011). Nonsurgical management of esophageal adenocarcinoma. Clin colorectal cancer, Vol.10 (3), pp. 165-170. show abstract

Poston, G.J. Tait, D. O'Connell, S. Bennett, A. Berendse, S. Grp, G.D. (2011). GUIDELINES Diagnosis and management of colorectal cancer: summary of NICE guidance. British medical journal, Vol.343.

Evans, J. Tait, D. Swift, I. Pennert, K. Tekkis, P. Wotherspoon, A. Chau, I. Cunningham, D. Brown, G. (2011). Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?. Dis colon rectum, Vol.54 (10), pp. 1251-1259. show abstract

BACKGROUND: In rectal cancer, the standard of care after the completion of radiotherapy is surgery at 6 to 8 weeks. However, there is variation regarding the timing of surgery. OBJECTIVE: This investigation aimed to audit the timing of surgery following radiotherapy and to compare perioperative morbidity and tumor downstaging in patients operated on, before and after the 6- to 8-week window. DESIGN: A retrospective review of rectal cancers treated preoperatively in our cancer network over a 27-month period. The effect of "time till surgery" of 6 to 8 weeks, <6 weeks, and >8 weeks on T downstaging and nodal downstaging was calculated by univariate and multivariate logistic regression analyses. SETTING: This study was conducted in an oncology tertiary referral center in the Southwest London Cancer Network. PATIENTS: Patients receiving preoperative radiotherapy for primary locally advanced rectal cancer undergoing subsequent surgical resection were eligible. MAIN OUTCOME MEASURES: The primary outcome measurement was time to surgery following the completion of (chemo) radiotherapy. Thirty-day perioperative morbidity and mortality and tumor and nodal downstaging were examined according to the timing of surgery. LIMITATIONS: This study was limited by its nonrandomized retrospective design and the lack of standardization of preoperative chemotherapy. RESULTS: Thirty-two (34%) patients underwent surgery at 6 to 8 weeks, 45 (47%) at >8 weeks, and 18 (19%) at <6 weeks after radiotherapy. Delay was attributed to scheduling in 87% of cases and to comorbidities in the remainder. T downstaging occurred in 6 (33.3%) patients in the <6 weeks group, in 12 (37.5%) in the 6 to 8 weeks group, and in 28 (62.2%) in >8 weeks group with no significant differences in perioperative morbidity. On multivariate analysis, T downstaging was significantly greater for the >8 weeks group (OR, 3.79; 95% CI: 1.11-12.99; P = .03). More patients were staged ypT0-T2, 19 of 45 (42%) in the >8 weeks group vs other groups, 14 of 50 (28%, P < .05). CONCLUSIONS: Following radiotherapy, surgery frequently occurs at >8 weeks and is associated with increased downstaging. The consequences on survival and perioperative morbidity warrant further investigation..

Hawkins, M.A. Aitken, A. Hansen, V.N. McNair, H.A. Tait, D.M. (2011). Cone beam CT verification for oesophageal cancer - impact of volume selected for image registration. Acta oncol, Vol.50 (8), pp. 1183-1190. show abstract

Alfa-Wali, M. Tait, D. Allen-Mersh, T. Tekkis, P. Nelson, M. Stebbing, J. Antoniou, A. Bower, M. (2011). Colorectal cancer in HIV positive individuals: The immunological effects of treatment. European journal of cancer, Vol.47 (16), pp. 2403-2407.

Chong, I. Hawkins, M. Hansen, V. Thomas, K. McNair, H. O'Neill, B. Aitken, A. Tait, D. (2011). Quantification of organ motion during chemoradiotherapy of rectal cancer using cone-beam computed tomography. Int j radiat oncol biol phys, Vol.81 (4), pp. e431-e438. show abstract

Hawkins, M.A. Hafeez, S. Bedford, J.L. Warrington, A.P. Tait, D.M. (2011). Evaluation of Respiratory-adapted Volumetric Modulated Arc Radiotherapy (VMAT) Planning for Gastro-esophageal Malignancies. International journal of radiation oncology biology physics, Vol.81 (2), pp. S323-S324.

Hawkins, M.A. Brooks, C. Hansen, V.N. Aitken, A. Tait, D.M. (2010). Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. Int j radiat oncol biol phys, Vol.77 (2), pp. 378-383. show abstract

Chua, Y.J. Barbachano, Y. Cunningham, D. Oates, J.R. Brown, G. Wotherspoon, A. Tait, D. Massey, A. Tebbutt, N.C. Chau, I. (2010). Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet oncol, Vol.11 (3), pp. 241-248. show abstract

BACKGROUND: Patients with poor-risk rectal cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy and optimum surgery. We aimed to assess the safety and long-term efficacy of neoadjuvant chemotherapy with capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision, a treatment strategy developed to enhance the outcome of this population. METHODS: Between November, 2001, and August, 2005, we enrolled eligible patients with poor-risk rectal cancer defined by high-resolution MRI and without metastatic disease. The protocol was amended in January, 2004, following clinically significant cardiotoxic events (nine events in eight of 77 patients), to exclude patients with a recent history of clinically significant cardiac problems. Patients received 12 weeks of neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks) followed by chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily), total mesorectal excision, and 12 weeks of postoperative adjuvant capecitabine (1250 mg/m2 twice daily for 14 days every 3 weeks). The primary endpoint was pathological complete response rate. We followed up patients for a median of 55 months (IQR 47-67). Efficacy analyses were undertaken for the intention-to-treat population, unless otherwise specified. This study is registered with ClinicalTrials.gov, number NCT00220051. FINDINGS: 105 eligible patients were enrolled. Radiological response rates after neoadjuvant chemotherapy and chemoradiotherapy were 74% (78/105) and 89% (93/105), respectively. 97 patients underwent surgery, of whom 95 underwent total mesorectal excision, of whom 93 had microscopically clear resection margins and 21 had pathological complete response (21/105 [20%]). 3-year progression-free and overall survival were 68% (95% CI 59-77) and 83% (76-91), respectively. 3-year relapse-free survival for patients who had complete resection was 74% (65-83). Following the protocol amendment for cardiovascular safety, only one further thromboembolic event was reported (fatal pulmonary embolism). INTERPRETATION: Intensification of systemic therapy with neoadjuvant combination chemotherapy before standard treatment is feasible in poor-risk potentially operable rectal cancer, with acceptable safety and promising long-term outcomes. Future development of this multidisciplinary treatment strategy in randomised trials is warranted. FUNDING: UK National Health Service, Sanofi-Aventis..

Saleem, A. Jackson, A. Mukherjee, S. Stones, N. Crosby, T. Tait, D. Price, P. Radiotherapy, A.C. (2010). Radiotherapy in the Management of Unresectable Locally Advanced Pancreatic Cancer: a Survey of the Current UK Practice of Clinical Oncologists. Clinical oncology, Vol.22 (4), pp. 257-260.

Wedlake, L.J. Thomas, K. Lalji, A. Blake, P. Khoo, V.S. Tait, D. Andreyev, H.J. (2010). Predicting late effects of pelvic radiotherapy: is there a better approach?. Int j radiat oncol biol phys, Vol.78 (4), pp. 1163-1170. show abstract

Gami, B. Thomas, K. Lalji, A. Blake, P. Khoo, V. Tait, D. Andreyev, H.J. (2009). Are Chronic Gastrointestinal Symptoms Developing after Radical Pelvic Radiotherapy Related to the Development of Urinary or Sexual Problems: Preliminary Data. Clinical oncology, Vol.21 (3), pp. 262-262.

Wedlake, L. Thomas, K. Lalji, A. Blake, P. Tait, D. Khoo, V. Andreyev, H.J. (2009). Is Peak Gastrointestinal Toxicity during Pelvic Radiotherapy a Better Predictor of Late Effects than Acute Cumulative Toxicity?. Clinical oncology, Vol.21 (3), pp. 247-248.

Drzymala, M. Hawkins, M.A. Henrys, A.J. Bedford, J. Norman, A. Tait, D.M. (2009). The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. Br j radiol, Vol.82 (976), pp. 321-327. show abstract

O'Neill, B.D. Salerno, G. Thomas, K. Tait, D.M. Brown, G. (2009). MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. Br j radiol, Vol.82 (978), pp. 509-513. show abstract

Martin, S. Mannino, M. Rostom, A. Tait, D. Donovan, E. Eagle, S. Haviland, J. Yarnold, J. (2008). Acute toxicity and 2-year adverse effects of 30 Gy in five fractions over 15 days to whole breast after local excision of early breast cancer. Clinical oncology, Vol.20 (7), pp. 502-4.

McGough, C. Wedlake, L. Baldwin, C. Hackett, C. Norman, A.R. Blake, P. Harrington, K. Tait, D. Khoo, V. Frost, G. Andreyev, H.J. (2008). Clinical trial: normal diet vs partial replacement with oral E028 formula for the prevention of gastrointestinal toxicity in cancer patients undergoing pelvic radiotherapy. Aliment pharmacol ther, Vol.27 (11), pp. 1132-1139. show abstract

Koh, D.-. Chau, I. Tait, D. Wotherspoon, A. Cunningham, D. Brown, G. (2008). Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int j radiat oncol biol phys, Vol.71 (2), pp. 456-461. show abstract

Koh, D.M. Dzik-Jurasz, A. O'Neill, B. Tait, D. Husband, J.E. Brown, G. (2008). Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br j radiol, Vol.81 (962), pp. 91-98. show abstract

Borghesi, S. Hawkins, M.A. Tait, D. (2008). Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin oncol (r coll radiol), Vol.20 (3), pp. 221-226. show abstract

Wedlake, L. McGough, C. Hackett, C. Thomas, K. Blake, P. Harrington, K. Tait, D. Khoo, V. Dearnaley, D. Andreyev, H.J. (2008). Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa?. Aliment pharmacol ther, Vol.27 (10), pp. 980-987. show abstract

Williams, M.V. Drinkwater, K.J. Jones, A. O'Sullivan, B. Tait, D. (2008). Waiting times for systemic cancer therapy in the United Kingdom in 2006. British journal of cancer, Vol.99 (5), pp. 695-703.

Haviland, J.S. Ashton, A. Broad, B. Gothard, L. Owen, J.R. Tait, D. Sydenham, M.A. Yarnold, J.R. Bliss, J.M. (2008). Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. Clin oncol (r coll radiol), Vol.20 (7), pp. 497-501. show abstract

Hawkins, M.A. Tait, D. (2008). Locally advanced non-metastatic pancreatic cancer - Can we do more?. Clinical oncology, Vol.20 (7), pp. 532-534.

Wolstenholme, V. Hawkins, M. Ashley, S. Tait, D. Ross, G. (2008). HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast, Vol.17 (6), pp. 661-665. show abstract

McGough, C. Wedlake, L. Hackett, C. Norman, A. Frost, G. Blake, P. Tait, D. Khoo, V. Harrington, K. Andreyev, H.J. (2007). Use of simple biological markers to monitor gastrointestinal toxicity during pelvic radiotherapy. Clinical oncology, Vol.19 (3), pp. S39-1.

Donovan, E. Bleakley, N. Denholm, E. Evans, P. Gothard, L. Hanson, J. Peckitt, C. Reise, S. Ross, G. Sharp, G. Symonds-Tayler, R. Tait, D. Yarnold, J. Breast Technology Group, (2007). Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother oncol, Vol.82 (3), pp. 254-264. show abstract

BACKGROUND: Radiation dose distributions created by two dimensional (2D) treatment planning are responsible for partial volumes receiving >107% of the prescribed dose in a proportion of patients prescribed whole breast radiotherapy after tumour excision of early breast cancer. These may contribute to clinically significant late radiation adverse effects. AIM: To test three dimensional (3D) intensity modulated radiotherapy (IMRT) against 2D dosimetry using standard wedge compensators in terms of late adverse effects after whole breast radiotherapy. METHODS: Three hundred and six women prescribed whole breast radiotherapy after tumour excision for early stage cancer were randomised to 3D IMRT (test arm) or 2D radiotherapy delivered using standard wedge compensators (control arm). All patients were treated with 6 or 10MV photons to a dose of 50Gy in 25 fractions to 100% in 5 weeks followed by an electron boost to the tumour bed of 11.1Gy in 5 fractions to 100%. The primary endpoint was change in breast appearance scored from serial photographs taken before radiotherapy and at 1, 2 and 5 years follow up. Secondary endpoints included patient self-assessments of breast discomfort, breast hardness, quality of life and physician assessments of breast induration. Analysis was by intention to treat. RESULTS: 240 (79%) patients with 5-year photographs were available for analysis. Change in breast appearance was identified in 71/122 (58%) allocated standard 2D treatment compared to only 47/118 (40%) patients allocated 3D IMRT. The control arm patients were 1.7 times more likely to have a change in breast appearance than the IMRT arm patients after adjustment for year of photographic assessment (95% confidence interval 1.2-2.5, p=0.008). Significantly fewer patients in the 3D IMRT group developed palpable induration assessed clinically in the centre of the breast, pectoral fold, infra-mammary fold and at the boost site. No significant differences between treatment groups were found in patient reported breast discomfort, breast hardness or quality of life. CONCLUSION: This analysis suggests that minimisation of unwanted radiation dose inhomogeneity in the breast reduces late adverse effects. Incidence of change in breast appearance was statistically significantly higher in patients in the standard 2D treatment arm compared with the IMRT arm. A beneficial effect on quality of life remains to be demonstrated..

Coolens, C. White, M.J. Crum, W.R. Charles-Edwards, L. O'Neill, B. Tait, D. Hawkins, M. (2007). Feasibility of free-breathing respiratory gated liver radiotherapy with MRI-derived models. Clinical oncology, Vol.19 (3), pp. S13-S13.

O'Neill, B.D. Brown, G. Heald, R.J. Cunningham, D. Tait, D.M. (2007). Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet oncol, Vol.8 (7), pp. 625-633. show abstract

O'Neill, B.D. Brown, G. Cunningham, D. Heald, R.J. Tait, D.M. (2007). Chemoradiotherapy alone for rectal cancer: A word of caution - Reply. Lancet oncology, Vol.8 (10), pp. 862-863.

Sultana, A. Smith, C.T. Cunningham, D. Starling, N. Tait, D. Neoptolemos, J.P. Ghaneh, P. (2007). Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. British journal of cancer, Vol.96 (8), pp. 1183-1190.

Guerrero Urbano, M.T. Henrys, A.J. Adams, E.J. Norman, A.R. Bedford, J.L. Harrington, K.J. Nutting, C.M. Dearnaley, D.P. Tait, D.M. (2006). Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int j radiat oncol biol phys, Vol.65 (3), pp. 907-916. show abstract

Khalid, U. McGough, C. Hackett, C. Blake, P. Harrington, K.J. Khoo, V.S. Tait, D. Norman, A.R. Andreyev, H.J. (2006). A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int j radiat oncol biol phys, Vol.64 (5), pp. 1432-1441. show abstract

Chau, I. Brown, G. Cunningham, D. Tait, D. Wotherspoon, A. Norman, A.R. Tebbutt, N. Hill, M. Ross, P.J. Massey, A. Oates, J. (2006). Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J clin oncol, Vol.24 (4), pp. 668-674. show abstract

Chau, I. Cunningham, D. Tait, D. Brown, G. (2006). Role of neoadjuvant chemotherapy in rectal cancer: Interpretation of the EXPERT study - Reply. Journal of clinical oncology, Vol.24 (28), pp. 4665-4666.

Burton, S. Brown, G. Daniels, I. Norman, A. Swift, I. Abulafi, M. Wotherspoon, A. Tait, D. (2006). MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: Treatment with radiotherapy and chemotherapy. International journal of radiation oncology biology physics, Vol.65 (2), pp. 445-451.

Tait, D.M. Hardy, J. (2006). Consent for investigating and treating adults with cancer. Clin oncol (r coll radiol), Vol.18 (1), pp. 23-29. show abstract

McGough, C. Peacock, N. Hackett, C. Baldwin, C. Norman, A. Frost, G. Blake, P. Tait, D. Khoo, V. Harrington, K. Whelan, K. Andreyev, H.J. (2006). Taste preferences for oral nutrition supplements in patients before and after pelvic radiotherapy: a double-blind controlled study. Clin nutr, Vol.25 (6), pp. 906-912. show abstract

Heald, R.J. O'Neill, B.D. Moran, B. Brown, G. Darzi, A.W. Wotherspoon, A.C. Cunningham, D. Tait, D.M. (2006). MRI in predicting curative resection of rectal cancer - New dilemma in multidisciplinary team management. Bmj-british medical journal, Vol.333 (7572), pp. 808-808. full text

O'Brien, M.E. Borthwick, A. Rigg, A. Leary, A. Assersohn, L. Last, K. Tan, S. Milan, S. Tait, D. Smith, I.E. (2006). Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. British journal of cancer, Vol.95 (12), pp. 1632-1636.

Williams, H.R. Vlavianos, P. Blake, P. Dearnaley, D.P. Tait, D. Andreyev, H.J. (2005). The significance of rectal bleeding after pelvic radiotherapy. Aliment pharmacol ther, Vol.21 (9), pp. 1085-1090. show abstract

Andreyev, H.J. Vlavianos, P. Blake, P. Dearnaley, D. Norman, A.R. Tait, D. (2005). Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?. Int j radiat oncol biol phys, Vol.62 (5), pp. 1464-1471. show abstract

PURPOSE: To analyze the cause of GI symptoms after pelvic radiotherapy (RT) in a consecutive series of patients with symptoms beginning after RT. A striking lack of evidence is available concerning the optimal treatment for the 50% of patients who develop permanent changes in bowel habits affecting their quality of life after pelvic RT. As a result, in the UK, most such patients are never referred to a gastroenterologist. METHODS AND MATERIALS: All diagnoses were prospectively recorded from a consecutive series of patients with symptoms that started after RT and who were referred during a 32-month period to a gastroenterology clinic. Patients either underwent direct access flexible sigmoidoscopy or were investigated in a standard manner by one gastroenterologist after first being seen in the clinic. RESULTS: A total of 265 patients referred from 15 institutions were investigated. They included 90 women (median age, 61.5 years; range, 22-84 years) and 175 men (median age, 70 years; range, 31-85 years). RT had been completed a median of 3 years (range, 0.1-34 years) before the study in the women and 2 years (range, 0-21 years) before in the men. Of the 265 patients, 171 had primary urologic, 78 gynecologic, and 16 GI tumors. The GI symptoms included rectal bleeding in 171, urgency in 82, frequency in 80, tenesmus, discomfort, or pain in 79, fecal incontinence in 79, change in bowel habit in 42, weight loss in 19, vomiting without other obstructive symptoms in 18, steatorrhea in 7, nocturnal defecation in 8, obstructive symptoms in 4, and other in 24. After investigation, significant neoplasia was found in 12%. One-third of all diagnoses were unrelated to the previous RT. More than one-half of the patients had at least two diagnoses. Many of the abnormalities diagnosed were readily treatable. The symptoms were generally unhelpful in predicting the diagnosis, with the exception of pain, which was associated with neoplasia (p < 0.001). CONCLUSION: The results of our study have shown that radiation enteritis is not a single disease entity. More than one-half of the patients had more than one GI diagnosis contributing to their symptoms. After pelvic RT, specific GI symptoms were not a reliable measure of the underlying diagnoses, and the evaluation of new GI symptoms is worthwhile. An algorithm for this purpose is proposed..

Yamold, J. Donovan, E. Bleackley, N. Reise, S. Peckitt, C. Patel, S. Sharp, G. Ross, G. Tait, D. Evans, P. (2005). Randomised trial of standard 2D radiotherapy (RT) versus 3D intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Ejc supplements, Vol.3 (2), pp. 390-1.

Chau, I. Norman, A.R. Cunningham, D. Tait, D. Ross, P.J. Iveson, T. Hill, M. Hickish, T. Lofts, F. Jodrell, D. Webb, A. Oates, J.R. (2005). A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann oncol, Vol.16 (4), pp. 549-557. show abstract

Gothard, L. Cornes, P. Brooker, S. Earl, J. Glees, J. Hall, E. Peckitt, C. Tait, D. Yarnold, J. (2005). Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiotherapy and oncology, Vol.75 (3), pp. 334-8.

Chau, I. Norman, A.R. Cunningham, D. Iveson, T. Hill, M. Hickish, T. Lofts, F. Jodrell, D. Webb, A. Tait, D. Ross, P.J. Shellito, P. Oates, J.R. (2005). Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur j cancer, Vol.41 (11), pp. 1551-1559. show abstract

Olopade, F.A. Norman, A. Blake, P. Dearnaley, D.P. Harrington, K.J. Khoo, V. Tait, D. Hackett, C. Andreyev, H.J. (2005). A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy. Br j cancer, Vol.92 (9), pp. 1663-1670. show abstract

After radiotherapy for pelvic cancer, chronic gastrointestinal problems may affect quality of life (QOL) in 6-78% of patients. This variation may be due to true differences in outcome in different diseases, and may also represent the inadequacy of the scales used to measure radiotherapy-induced gastrointestinal side effects. The aim of this study was to assess whether outcome measures used for nonmalignant gastrointestinal disease are useful to detect gastrointestinal morbidity after radiotherapy. Results obtained from a Vaizey Incontinence questionnaire and a modified Inflammatory Bowel Disease questionnaire (IBDQ)--both patient completed--were compared to those from a staff administered Late Effects on Normal Tissue (LENT)--Subjective, Objective, Management and Analytic (SOMA) questionnaire in patients who had completed radiotherapy for a pelvic tumour at least 3 months previously. In all, 142 consecutive patients were recruited, 72 male and 70 female, median age 66 years (range 26-90 years), a median of 27 (range 3-258) months after radiotherapy. In total, 62 had been treated for a gynaecological, 58, a urological and 22, a gastrointestinal tract tumour. Of these, 21 had undergone previous gastrointestinal surgery and seven suffered chronic gastrointestinal disorders preceding their diagnosis of cancer. The Vaizey questionnaire suggested that 27% patients were incontinent for solid stools, 35% for liquid stools and 37% could not defer defaecation for 15 min. The IBDQ suggested that 89% had developed a chronic change in bowel habit and this change significantly affected 49% patients: 44% had more frequent or looser bowel movements, 30% were troubled by abdominal pain, 30% were troubled by bloating, 28% complained of tenesmus, 27% were troubled by their accidental soiling and 20% had rectal bleeding. At least 34% suffered emotional distress and 22% impairment of social function because of their bowels. The small intestine/colon SOMA median score was 0.1538 (range 0-1) and the rectal SOMA median score was 0.1428 (range 0-1). Pearson's correlations for the IBDQ score and small intestine/colon SOMA score was -0.630 (P<0.001), IBDQ and rectum SOMA -0.616 (P<0.001), IBDQ and Vaizey scores -0.599 (P<0.001), Vaizey and small intestine/colon SOMA 0.452 (P<0.001) and Vaizey and rectum SOMA 0.760 (P<0.001). After radiotherapy for a tumour in the pelvis, half of all patients develop gastrointestinal morbidity, which affects their QOL. A modified IBDQ and Vaizey questionnaire are reliable in assessing new gastrointestinal symptoms as well as overall QOL and are much easier to use than LENT SOMA..

Cominos, M. Mosleh-Shirazi, M.A. Tait, D. Henrys, A. Cornes, P. (2005). Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. Br j radiol, Vol.78 (936), pp. 1069-1074. show abstract

Tait, D. (2005). Advances in chemoradiation therapy in rectal cancer: the impact of imaging. Br j radiol, Vol.78 Spec No 2, pp. S131-S137.

Price, T.J. Ross, P.J. Hickish, T. Tait, D. Norman, A.R. Ford, H.E. Middleton, G. Sumpter, K. Hill, M. Oates, J. Cunningham, D. (2004). Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin colorectal cancer, Vol.3 (4), pp. 235-242. show abstract

Urbano, M.T. Tait, D.M. (2004). Can the irradiated uterus sustain a pregnancy? A literature review. Clin oncol (r coll radiol), Vol.16 (1), pp. 24-28. show abstract

Trapp, J.V. Warrington, A.P. Partridge, M. Philps, A. Glees, J. Tait, D. Ahmed, R. Leach, M.O. Webb, S. (2004). Measurement of the three-dimensional distribution of radiation dose in grid therapy. Phys med biol, Vol.49 (19), pp. N317-N323. show abstract

Tait, D.M. (2004). Multi-modality treatment in oesophageal cancer: a curse for radiotherapy progress. Radiotherapy and oncology, Vol.73 (2), pp. 115-117.

Chau, I. Allen, M.J. Cunningham, D. Norman, A.R. Brown, G. Ford, H.E. Tebbutt, N. Tait, D. Hill, M. Ross, P.J. Oates, J. (2004). The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J clin oncol, Vol.22 (8), pp. 1420-1429. show abstract

Tebbutt, N.C. Norman, A.R. Cunningham, D. Hill, M.E. Tait, D. Oates, J. Livingston, S. Andreyev, J. (2003). Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut, Vol.52 (4), pp. 568-573. show abstract

Neoptolemos, J.P. Cunningham, D. Friess, H. Bassi, C. Stocken, D.D. Tait, D.M. Dunn, J.A. Dervenis, C. Lacaine, F. Hickey, H. Raraty, M.G. Ghaneh, P. Buchler, M.W. (2003). Adjuvant therapy in pancreatic cancer: historical and current perspectives. Annals of oncology, Vol.14 (5), pp. 675-692.

Chau, I. Allen, M. Cunningham, D. Tait, D. Brown, G. Hill, M. Sumpter, K. Rhodes, A. Wotherspoon, A. Norman, A.R. Hill, A. Massey, A. Prior, Y. (2003). Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br j cancer, Vol.88 (7), pp. 1017-1024. show abstract

Clarke, P.A. George, M.L. Easdale, S. Cunningham, D. Swift, R.I. Hill, M.E. Tait, D.M. Workman, P. (2003). Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer res, Vol.63 (20), pp. 6855-6863. show abstract

Gami, B. Harrington, K. Blake, P. Dearnaley, D. Tait, D. Davies, J. Norman, A.R. Andreyev, H.J. (2003). How patients manage gastrointestinal symptoms after pelvic radiotherapy. Aliment pharmacol ther, Vol.18 (10), pp. 987-994. show abstract

BACKGROUND: Approximately 13,000 patients undergo pelvic radiotherapy annually in the UK. It is not clear how frequently patients develop a permanent change in bowel habit after pelvic radiotherapy that affects their quality of life because the measures of gastrointestinal toxicity used in trials in the past have generally been inadequate. It has been suggested that patients who are symptomatic are only rarely referred to a gastroenterologist and it is not known how patients manage their symptoms. METHODS: Patients who had completed radiotherapy for pelvic cancer at least 1 year previously were invited to answer 30 structured questions in a face-to-face interview to determine the frequency of gastrointestinal symptoms and what orthodox, dietary and complementary therapies they used to deal with them. They were also asked to score the effectiveness of the measures they had taken. RESULTS: One hundred and seven patients were recruited [35 males; median age, 65 years (range, 35-80 years); 72 females; median age, 67.5 years (range, 31-87 years)]. Eight had been treated for a gastrointestinal primary tumour, 34 for a urological tumour and 65 for gynaecological tumours. Eighty-seven patients (81%) described new-onset gastrointestinal problems starting after radiotherapy. These symptoms affected the quality of life in 56 patients (52%). Significant effects on the quality of life were caused by diarrhoea or constipation (n = 53), faecal leakage (n = 19), abdominal, rectal or perineal pain (n = 14) and rectal bleeding (n = 6). Fifty-nine patients had seen a doctor for their symptoms (86% found this helpful), 12 had seen a dietician or nurse (50% found this helpful) and 14 had seen alternative practitioners (88% found this helpful). Dietary manipulation generally did not improve symptoms, except in a small group of patients (14/15) who avoided raw vegetables to great benefit. CONCLUSIONS: At least 1 year after pelvic radiotherapy, gastrointestinal symptoms which have an adverse effect on the quality of life may be more common than generally reported. Patients found that advice from doctors and alternative practitioners was equally valuable. Dietary manipulation was generally unhelpful for gastrointestinal symptoms after pelvic radiotherapy, although the role of eliminating raw vegetables may benefit from further evaluation..

Taylor, R.E. Bailey, C.C. Robinson, K. Weston, C.L. Ellison, D. Ironside, J. Lucraft, H. Gilbertson, R. Tait, D.M. Walker, D.A. Pizer, B.L. Imeson, J. Lashford, L.S. (2003). Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology United Kingdom Children's Cancer Study Group PNET-3 study. Journal of clinical oncology, Vol.21 (8), pp. 1581-1591.

Saini, A. Norman, A.R. Cunningham, D. Chau, I. Hill, M. Tait, D. Hickish, T. Iveson, T. Lofts, F. Jodrell, D. Ross, P.J. Oates, J. (2003). Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br j cancer, Vol.88 (12), pp. 1859-1865. show abstract

Andreyev, H.J. Amin, Z. Blake, P. Dearnaley, D. Tait, D. Vlavianos, P. (2002). Gastrointestinal symptoms after radiotherapy for pelvic cancer. Gut, Vol.50, pp. A61-1.

Powles, R. Sirohi, B. Treleaven, J. Kulkarni, S. Tait, D. Singhal, S. Mehta, J. (2002). The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood, Vol.100 (5), pp. 1641-1647. show abstract

Essapen, S. Knowles, C. Norman, A. Tait, D. (2002). Accuracy of set-up of thoracic radiotherapy: prospective analysis of 24 patients treated with radiotherapy for lung cancer. Br j radiol, Vol.75 (890), pp. 162-169. show abstract

Mehta, J. Powles, R. Sirohi, B. Treleaven, J. Kulkarni, S. Saso, R. Tait, D. Singhal, S. (2002). Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?. Bone marrow transplant, Vol.29 (10), pp. 853-859. show abstract

Waters, J.S. Tait, D. Cunningham, D. Padhani, A.R. Hill, M.E. Falk, S. Lofts, F. Norman, A. Oates, J. Hill, A. (2002). A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Ann oncol, Vol.13 (11), pp. 1763-1770. show abstract

George, M.L. Dzik-Jurasz, A.S. Brown, G. Padhani, A.R. Husband, J. Leach, M.O. Rowland, I.J. Hill, M.E. Cunningham, D.C. Tait, D. Eccles, S.A. Swift, R.I. (2001). Dynamic contrast MRI (DCMRI) assessment of tumour permeability in locally advanced rectal cancer: a prognostic indicator for response to chemoradiotherapy. British journal of surgery, Vol.88, pp. 25-1.

Essapen, S. Knowles, C. Tait, D. (2001). Variation in size and position of the planning target volume in the transverse plane owing to respiratory movement during radiotherapy to the lung. Br j radiol, Vol.74 (877), pp. 73-76. show abstract

Nalder, C.A. Bidmead, A.M. Mubata, C.D. Tait, D. Beardmore, C. (2001). Influence of a vac-fix immobilization device on the accuracy of patient positioning during routine breast radiotherapy. Br j radiol, Vol.74 (879), pp. 249-254. show abstract

Continued use of basic planning and treatment techniques, in contrast to the improved methods implemented at many other anatomical sites, has emphasized the need for improved breast dosimetry. Any future technique delivering a superior three-dimensional dose distribution will be of maximum benefit if set-up errors are minimized. To determine the influence of vacuum moulded bag (vac-fix) immobilization on routine breast radiotherapy, 17 patients received half their radiotherapy fractions using our standard breast board technique and half using a vac-fix device positioned on the breast board. Treatment accuracy and reproducibility were assessed for each technique using daily electronic portal imaging and were analysed in terms of random and systematic translational and rotational displacements of treatment fields with respect to corresponding simulation images. In addition, patients completed a short questionnaire aimed at determining which technique they preferred. Results showed that random errors for the two techniques did not differ significantly. Approximately 80% of random translations recorded were less than 3 mm and 80% of random rotations were less than 1.5 degrees. Systematic errors showed some improvement with the vac-fix system. In the anteroposterior direction, approximately 80% of systematic errors were less than 4 mm for both techniques, but in the superoinferior direction the 80% point was reduced from 5.0 mm for the standard set-up to 2.7 mm for treatment in vac-fix. For rotational systematic errors, the corresponding value dropped from 1.8 degrees for the standard set-up to 1.1 degrees in vac-fix. Therefore, for many patients, additional use of a vac-fix device improved the transfer of the planned set-up from simulator to treatment unit. Additionally, answers to the questionnaire indicated that patients generally favoured the vac-fix system over use of the breast board alone. In conclusion, however, introduction of vac-fix immobilization for all patients was not thought justified as the improvements demonstrated are not likely to be clinically significant with the present treatment technique..

Nutting, C.M. Bedford, J.L. Cosgrove, V.P. Tait, D.M. Dearnaley, D.P. Webb, S. (2001). A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother oncol, Vol.61 (2), pp. 157-163. show abstract

George, M.L. Dzik-Jurasz, A.S. Padhani, A.R. Brown, G. Tait, D.M. Eccles, S.A. Swift, R.I. (2001). Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. British journal of surgery, Vol.88 (12), pp. 1628-9.

Sirohi, B. Powles, R. Singhal, S. Treleaven, J. Horton, C. Tait, D. Kulkarni, S. Saso, R. Mehta, J. (2001). Melphalan-total body irradiation and allogeneic transplantation from HLA-identical siblings for acute myeloid leukemia in first remission: Higher relapse after marrow-derived stem cell grafts compared to blood despite similar chronic graft-versus-host disease. Blood, Vol.98 (11), pp. 381B-381B.

Mehta, J. Powles, R. Sirohi, B. Treleaven, J. Swansbury, G.J. Min, T. Kulkarni, S. Saso, R. Tait, D. Singhal, S. (2001). Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: Is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes?. Blood, Vol.98 (11), pp. 716A-717A.

Sirohi, B. Powles, R. Singhal, S. Treleaven, J. Saso, R. Kulkarni, S. Horton, C. Tait, D. Mehta, J. (2001). The impact of consolidation chemotherapy on the outcome of autotransplantation for acute myeloid leukemia in first remission: Single-center experience of 118 adult patients. Blood, Vol.98 (11), pp. 690A-690A.

Singhal, S. Powles, R. Sirohi, B. Treleaven, J. Kulkarni, S. Saso, R. Tait, D. Mehta, J. (2001). Enhancement of the anti-tumor efficacy of allogeneic transplantation with the use of blood-derived stem cells: 5-year follow-up of a prospective study comparing marrow and blood allografts. Blood, Vol.98 (11), pp. 419A-419A.

Sirohi, B. Powles, R. Singhal, S. Treleaven, J. Kulkarni, S. Saso, R. Tait, D. Mehta, J. (2001). 20-year follow-up of allogeneic bone marrow transplantation with cyclophosphamide-TBI and cyclosporine for acute myeloid leukemia in first complete remission. Blood, Vol.98 (11), pp. 402A-402A.

Kulkarni, S. Powles, R. Sirohi, B. Treleaven, J. Horton, C. Saso, R. Tait, D. Hjjiyiannakis, P. Singhal, S. Mehta, J. (2001). Single centre analysis of allogeneic hematopoetic stem cell transplant for acute leukaemia in first complete remission: Comparison of two single fraction dose schedules (9 5Gy or 10 5Gy). Blood, Vol.98 (11), pp. 195A-196A.

Dzik-Jurasz, A.S. Brooker, S. Husband, J.E. Tait, D. (2001). What is the prevalence of symptomatic or asymptomatic femoral head osteonecrosis in patients previously treated with chemoradiation? A magnetic resonance study of anal cancer patients. Clin oncol (r coll radiol), Vol.13 (2), pp. 130-134. show abstract

Kulkarni, S. Powles, R. Treleaven, J. Singhal, S. Horton, C. Sirohi, B. Bhagawati, N. Tait, D. Saso, R. Killick, S. Pinkerton, R. Atra, A. Meller, S. Mehta, J. (2000). Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. Bone marrow transplant, Vol.25 (4), pp. 365-370. show abstract

As there is concern regarding the high carcinogenic potential of melphalan (Mel), 725 patients with haematological malignancies who received allogeneic (n = 714) or syngeneic (n = 11) transplants over the last 26 years were followed-up to evaluate if melphalan was more likely to result in secondary malignant neoplasms (SMNs) than cyclophosphamide (Cy). Three hundred and ninety-five were treated with Cy/TBI and 330 with Mel/TBI. Twelve patients developed non-haematological SMN. Median time to develop a SMN was 7 years (range 2-17 years). Age-adjusted rate was significantly higher than in the general population (observed 12 expected 1.2, risk 10; P < 0.0001). The cumulative overall risk of developing a SMN at 2, 5, 10 and 15 years post transplant was 0.4% (95% CI 0.1-2.6%), 1.7% (95% CI 0.6-4.4%), 6.4% (95% CI 2.8-10.8%) and 6.6% (95% CI 3.4-12.4%), respectively. Even though age-adjusted rates were higher than the general population melphalan/TBI was not associated with higher age-adjusted risk than Cy/TBI (increased risk 7.9 vs 11.4; P = NS). The cumulative overall risk of SMNs was not different with CY/TBI or Mel/TBI (8/393 vs 4/363; 10 year risk 4.4%, 95% CI 1.8-10.6 vs 8.4%, 95% CI 2.9-22.9; P = NS). The risk was significantly higher with use of additional cranial or cranio-spinal irradiation (17.5% vs 2.7% at 10 years; P = 0.0241). Transplants for acute lymphatic leukaemia resulted in a higher incidence of SMNs than did transplants for other diseases (ALL: 17.4%, 95% CI 6.3-42.6%; other diseases: 3.4% (95% 1.3-8.5%, P = 0.0469). The risk of SMN for patients with chronic GVHD was 8.4% (95% CI 3.7-18.7%) as compared to 3.5% (95% CI 1-11.1%) for patients without chronic GVHD (P = NS). No factor was associated with independently increased risk in multivariate analysis. Use of melphalan and TBI for transplant conditioning does not appear to be associated with higher risk of second malignant neoplasms than cyclophosphamide and TBI..

Vaidya, S.J. Atra, A. Bahl, S. Pinkerton, C.R. Calvagna, V. Horton, C. Milan, S. Shepherd, V. Brain, C. Treleaven, J. Powles, R. Tait, D. Meller, S.T. (2000). Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up. Bone marrow transplant, Vol.25 (6), pp. 599-603. show abstract

Davidson, A. Tait, D.M. Payne, G.S. Hopewell, J.W. Leach, M.O. Watson, M. MacVicar, A.D. Britton, J.A. Ashley, S. (2000). Magnetic resonance spectroscopy in the evaluation of neurotoxicity following cranial irradiation for childhood cancer. British journal of radiology, Vol.73 (868), pp. 421-4.

Davidson, A. Payne, G. Leach, M.O. McVicar, D. Britton, J.M. Watson, M. Tait, D.M. (2000). Proton magnetic resonance spectroscopy ((1)H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer. Med pediatr oncol, Vol.35 (1), pp. 28-34. show abstract

Powles, R. Mehta, J. Kulkarni, S. Treleaven, J. Millar, B. Marsden, J. Shepherd, V. Rowland, A. Sirohi, B. Tait, D. Horton, C. Long, S. Singhal, S. (2000). Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet, Vol.355 (9211), pp. 1231-1237. show abstract

Hamilton, M.A. Tait, D. (2000). Metastatic paraganglioma causing spinal cord compression. Br j radiol, Vol.73 (872), pp. 901-904. show abstract

Singhal, S. Powles, R. Treleaven, J. Kulkarni, S. Sirohi, B. Horton, C. Millar, B. Shepherd, V. Tait, D. Saso, R. Rowland, A. Long, S. Mehta, J. (2000). A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?. Bone marrow transplant, Vol.26 (5), pp. 489-496. show abstract

Bedford, J.L. Viviers, L. Guzel, Z. Childs, P.J. Webb, S. Tait, D.M. (2000). A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother oncol, Vol.57 (2), pp. 183-193. show abstract

Powles, R. Mehta, J. Treleaven, J. Kulkarni, S. Sirohi, B. Horton, C. Tait, D. Long, S. Singhal, S. (2000). Blood or BM for allogeneic transplantation from hla-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM. Blood, Vol.96 (11), pp. 196A-196A.

Nutting, C. Camplejohn, R.S. Gilchrist, R. Tait, D. Blake, P. Knee, G. Yao, W.Q. Ross, G. Fisher, C. Eeles, R. (2000). A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy?. Clin oncol (r coll radiol), Vol.12 (5), pp. 300-304. show abstract

Cornes, P. Tait, D. (2000). Computerizing the cancer centre: The mathematics of survival. Clinical oncology, Vol.12 (5), pp. 337-337.

Viviers, L. Beford, J. Guzel, S. Childs, P. Webb, S. Tait, D. (1999). Oesophageal radiotherapy: Potential far dose escalation by conformal techniques. European journal of cancer, Vol.35, pp. S180-1.

Ashton, A. Balyckyi, J. Barton, R. Bolger, J. Cruickshank, C. Davidson, J. Dearnaley, D. Elyan, S. Harmer, C. Hoskin, P. Jose, C. Maitland, L. Melville, P. Meyer, L. Neal, A. Regan, J. Skeet, O. Skelton, L. Tait, D. Wardle, J. Wynne, C. Yarnold, J. (1999). 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiotherapy and oncology, Vol.52 (2), pp. 111-11.

Kulkarni, S. Rodriguez, M. Lafuente, A. Mateos, P. Mehta, J. Singhal, S. Saso, R. Tait, D. Treleaven, J.G. Powles, R.L. (1999). Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone marrow transplant, Vol.23 (8), pp. 803-807. show abstract

Kanagasabay, R.R. Lamb, P.M. Tait, D.M. Madden, B.P. (1999). Local radiotherapy for alveolar air leak. Journal of the royal society of medicine, Vol.92 (4), pp. 190-192.

Kulkarni, S. Powles, R.L. Treleaven, J.G. Singhal, S. Saso, R. Horton, C. Killick, S. Tait, D. Ramiah, V. Mehta, J. (1999). Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone marrow transplant, Vol.23 (7), pp. 675-680. show abstract

Tait, D.M. (1999). Management of colorectal cancer: haematology. Crit rev oncol hematol, Vol.30 (3), pp. 207-214.

Tait, D. Walters, J. Norman, A. Ross, P. Cunningham, D. (1999). The Royal Marsden experience with chemo-radiation protracted infusional (PVI) 5-FU and cisplatin with conformal radiotherapy (CR-RT) in locally advanced oesophageal cancer. British journal of cancer, Vol.80, pp. 58-58.

Price, T. Cunningham, D. Hickish, T. Tait, D. Norman, A. Ross, P.J. Middleton, G. Ford, H.E. Sumpter, K. Hill, M. (1999). Dose intensification of 5 fluorouracil by chronomodulation in a phase III trial for advanced colorectal carcinoma. British journal of cancer, Vol.80, pp. 20-20.

Tait, D. Dzik-Djuraz, A. Husband, J. Glees, J. Essapen, S. Abson, C. Brooker, S. (1999). MRI in the long term follow-up of patients treated with chemo-radiation (CRT) for anal cancer. British journal of cancer, Vol.80, pp. 57-57.

Tait, D. Glees, J.P. Brooker, S. Cook, A. Norman, A. (1999). Once weekly radiotherapy for patients with locally advanced or recurrent rectal cancer. British journal of cancer, Vol.80, pp. 57-57.

Tait, D. Walters, J. Norman, A. Ross, P. Cunningham, D. (1999). The royal marsden experience with chemo-radiation using protracted infusional (PVI) 5-fu and cisplatin with conformal radiotherapy (CR-RT) in locally advanced oesophageal cancer. European journal of cancer, Vol.35, pp. S142-S142.

Tait, D. Dzik-Djuraz, A. Husband, J. Glees, J. Essapen, S. Abson, C. Brooker, S. (1999). A prospective study of MRI in the staging, and response assessment of patients treated with chemo-radiation (CRT). European journal of cancer, Vol.35, pp. S155-S155.

Tait, D. Dzik-Djuraz, A. Husband, J. Glees, J. Essapen, S. Abson, G. Brooker, S. (1999). MRI in the long term follow up of patients treated with chemo-radiation (CRT) for anal cancer. European journal of cancer, Vol.35, pp. S150-S150.

Tait, D. Glees, J.P. Cook, A. Brooker, S. Norman, A. (1999). Once weekly radiotherapy for patients with locally advanced or recurrent rectal cancer. European journal of cancer, Vol.35, pp. S71-S71.

Brooker, S. Tait, D. Glees, J.P. Cook, A. Norman, A. (1999). The research nurses role in the study of patients recieving once weekly radiotherapy for locally advanced or recurrent rectal cancer. European journal of cancer, Vol.35, pp. S18-S18.

Lee, C.H. Tait, D. Nahum, A.E. Webb, S. (1999). Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br j radiol, Vol.72 (863), pp. 1078-1084. show abstract

Bhagwati, N.S. Powles, R.L. Sirohi, B. Treleaven, J.G. Horton, C.A. Tait, D. Mehta, J. Singhal, S. Kulkarni, S.S. (1999). Single center evaluation of long term follow-up of ABMT/PBSCT for first remission adult ALL: Potential for cure without excessive toxicity. Blood, Vol.94 (10), pp. 580A-580A.

Singhal, S. Powles, R. Treleaven, J. Kulkarni, S. Sirohi, B. Tait, D. Horton, C. Rowland, A. Long, S. Millar, B. Shepherd, V. Mehta, J. (1999). A low CD34+cell dose results in higher mortality and loner survival after blood or marrow stem cell transplantation from HLA-identical siblings: Should 2 x 10(6) CD34+cells/kg be considered the threshold?. Blood, Vol.94 (10), pp. 388B-388B.

Powles, R. Mehta, J. Kulkarni, S. Treleaven, J. Sirohi, B. Tait, D. Horton, C. Rowland, A. Long, S. Millar, B. Shepherd, V. Sanghal, S. (1999). More powerful graft-versus-tumor effects with blood-derived stem cells? Significantly lower relapse after blood stem cell allografts in a randomized study comparing allogeneic blood versus marrow transplantation. Blood, Vol.94 (10), pp. 164A-164A.

Dearnaley, D.P. Khoo, V.S. Norman, A.R. Meyer, L. Nahum, A. Tait, D. Yarnold, J. Horwich, A. (1999). Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet, Vol.353 (9149), pp. 267-272. show abstract

Guzel, Z. Bedford, J.L. Childs, P.J. Nahum, A.E. Webb, S. Oldham, M. Tait, D. (1998). A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress. British journal of radiology, Vol.71 (850), pp. 1076-7.

Dearnaley, D.P. Khoo, V. Norman, A. Meyer, L. Nahum, A. Tait, D. Yarnold, J. Horwich, A. (1998). Reduction of radiation induced rectal bleeding using radical conformal radiotherapy in induced radical prostate cancer: A randomised control trial. British journal of cancer, Vol.78, pp. 9-1.

Viviers, L. Bedford, J. Guzel, Z. Tait, D. Childs, P.J. Webb, S. Oldham, M. Nahum, A.E. (1998). Dose escalation using conformal techniques for oesophageal cancer in the setting of chemotherapy-radiation. British journal of cancer, Vol.78, pp. 38-1.

Mehta, J. Powles, R. Kulkarni, S. Treleaven, J. Singhal, S. Cunningham, D. Tait, D. Catovsky, D. (1998). Bone marrow transplantation for chronic lymphocytic leukemia. Bone marrow transplantation, Vol.21, pp. S78-S78.

Kulkarni, S. Powles, R. Singhal, S. Treleaven, J. Horton, C. Meller, S. Pinkerton, C.R. Atra, A. Tait, D. Mehta, J. (1998). Second cancers and non-autologous bone marrow transplantation for haematological malignancies: Single centre experience of 883 patients. Bone marrow transplantation, Vol.21, pp. S162-S162.

Treleaven, J. Powles, R. Singhal, S. Kulkarni, S. Tait, D. Horton, C. Mehta, J. (1998). Long-term outcome of patients who are alive and well two years after autografting for acute leukaemia. Bone marrow transplantation, Vol.21, pp. S8-S8.

Mehta, J. Powles, R. Treleaven, T. Kulkarni, S. Horton, C. Tait, D. Singhal, S. (1998). Long-term outcome of patients who are alive and well two years after allografting for acute leukaemia. Bone marrow transplantation, Vol.21, pp. S7-S7.

Powles, R. Kulkarni, S. Mehta, J. Treleaven, J. Millar, B. Shepherd, V. Tait, D. Antrum, J. Neville, F. Long, S. Rowland, A. Shaw, K. Singhal, S. (1998). A double-blind randomised study comparing the efficacy of allogeneic marrow versus blood stem cell transplantation. Bone marrow transplantation, Vol.21, pp. S35-S35.

Tait, D.M. (1998). Verification systems--tools or toys?. Br j radiol, Vol.71 (846), pp. 581-583.

Kulkarni, S. Powles, R. Singhal, S. Mehta, J. Treleaven, J. Horton, C. Meller, S. Pinkerton, C.R. Atra, A. Tait, D. (1998). Second cancers after non-autologous bone marrow transplantation for hematologic malignancies. British journal of haematology, Vol.102 (1), pp. 211-211.

Mehta, J. Powles, R. Kulkarni, S. Treleaven, J. Singhal, S. Saso, R. Tait, D. Catovsky, D. (1998). Melphalan-TBI and T-cell-nondepleted allografts for chronic lymphocytic leukemia: Long-term follow-up shows excellent anti-leukemic activity. Blood, Vol.92 (10), pp. 288A-288A.

Singhal, S. Powles, R. Treleaven, J. Kulkarni, S. Horton, C. Tait, D. Mehta, J. (1998). Melphalan-TBI for allogeneic transplantation in acute myeloid leukemia: Lack of veno-occlusive disease and hemorrhagic cystitis. Blood, Vol.92 (10), pp. 658A-658A.

Kulkarni, S. Powles, R. Mehta, J. Raje, N. Singhal, S. Horton, C. Tait, D. Treleaven, J. (1998). Allogeneic bone marrow transplantation for multiple myeloma. Blood, Vol.92 (10), pp. 352B-352B.

Powles, R. Kulkarni, S. Mehta, J. Treleaven, J. Millar, B. Shepherd, V. Tait, D. Rowland, A. Long, S. Singhal, S. (1998). Pattern of immune reconstitution after allograft: Results of double blind randomised trial of allogeneic bone marrow or peripheral blood stem cells transplantation. Blood, Vol.92 (10), pp. 141A-141A.

Essapen, S. Knowles, C. Norman, A. Tait, D. (1998). Accuracy of thoracic radiotherapy: Prospective analysis of 24 patients treated with non-palliative radiotherapy for lung cancer. British journal of cancer, Vol.78, pp. 7-7.

Taylor, R.E. Lucraft, H. Tait, D. (1998). Protocol compliance for radiotherapy in the UKCCSG/SIOP PNET-3 study. British journal of cancer, Vol.78, pp. 6-6.

Tait, D.M. Nahum, A.E. Meyer, L.C. Law, M. Dearnaley, D.P. Horwich, A. Mayles, W.P. Yarnold, J.R. (1997). Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother oncol, Vol.42 (2), pp. 121-136. show abstract

BACKGROUND: A prospective, randomized clinical trial to assess the effect of reducing the volume of irradiated normal tissue on acute reactions in pelvic radiotherapy accured 266 evaluable patients between 1988 and 1993. PURPOSE: This is the definitive analysis to assess the differences between the conformal and conventional arms of the trial. MATERIALS AND METHODS: In both arms, patients were treated with 6 MV X-rays using a 3-field technique (in all but 5 cases) consisting of an anterior and two wedged lateral or posterior oblique fields; in the conventional arm, rectangular fields were employed, whereas in the conformal arm, the fields were shaped with customized blocks drawn according to the beam's-eye-view of the target volume. The most common dosage was 64 Gy in 2-Gy fractions 5 times a week, although a subgroup (of ca. bladder patients) were treated with 30-36 Gy in once-a-week 6 Gy fractions. Each patients completed a comprehensive acute toxicity scoring questionnaire concentrating on bowel and bladder problems, tiredness and nausea, before the start of treatment, weekly during and for 3 weeks after the end of treatment and then monthly for a further 2 months. compliance was excellent. RESULTS: There were no differences between the patients in the two arms with respect to age, gender, tumour type (52% prostate, 41% bladder, 5% rectum, 2% other) fractionation/dosage, anterior field size, weight, or baseline symptoms. Substantial differences in normal-tissue volumes (rectum, bladder, etc.) were achieved: median high-dose volume (HDV) of 689 cm3 for the conformal technique versus 792 cm3 for the conventional. A clear pattern of an increase in symptoms during RT, followed by a decrease after RT, was observed for the patient group as a whole. However, a very extensive analysis has not revealed any (statistically) significant differences between the two arms in level of symptoms, nor in medication prescribed. The disparity between our findings and those of other, non-randomized studies is discussed. CONCLUSIONS: The data on late effects must be collected and analyzed before any definite conclusions can be drawn on the benefits of conformal therapy in the pelvis..

Hjiyiannakis, P. Mehta, J. Milan, S. Powles, R. Hinson, J. Tait, D. (1997). melphalan, single-fraction total-body irradiation and allogeneic bone marrow transplantation for acute leukemia: review of transplant-related mortality. Leuk lymphoma, Vol.25 (5-6), pp. 565-572. show abstract

Tait, D.M. Nahum, A.E. (1997). Acute toxicity in pelvic radiotherapy; A randomised trial of conformal versus conventional treatment - Reply. Radiotherapy and oncology, Vol.44 (3), pp. 295-296.

Mehta, J. Powles, R. Treleaven, J. Kulkarni, S. Singhal, S. Saso, R. Hamblin, M. Rege, K. Cunningham, D. Killick, S. Tait, D. Catovsky, D. (1997). Bone marrow transplantation for chronic lymphocytic leukemia. Blood, Vol.90 (10), pp. 4503-4503.

Kulkarni, S. Powles, R. Treleaven, J. Singhal, S. Sastry, P. Raje, N. Tait, D. Mehta, J. (1997). Allogeneic bone marrow transplantation for multiple myeloma. Blood, Vol.90 (10), pp. 4497-4497.

Kulkarni, S. Powles, R. Singhal, S. Treleaven, J. Horton, C. Meller, S. Pinkerton, C.R. Atra, A. Tait, D. Mehta, J. (1997). Second cancers after non-autologous bone marrow transplantation for hematologic malignancies: Single-center experience of 883 patients. Blood, Vol.90 (10), pp. 1674-1674.

Mehta, J. Powles, R. Treleaven, J. Kulkarni, S. Horton, C. Tait, D. Singhal, S. (1997). Long-term outcome of patients who are alive and well two years after allografting for acute leukemia. Blood, Vol.90 (10), pp. 1692-1692.

Treleaven, J. Powles, R. Singhal, S. Kulkarni, S. Tait, D. Horton, C. Mehta, J. (1997). Long-term outcome of patients who are alive and well two years after autografting for acute leukemia. Blood, Vol.90 (10), pp. 1691-1691.

Singhal, S. Powles, R. Treleaven, J. Kulkarni, S. Horton, C. Tait, D. Mehta, J. (1997). Sequential high-dose therapy of acute lymphoblastic leukemia in adult patients: Long-term follow-up. Blood, Vol.90 (10), pp. 1033-1033.

Powles, R. Treleaven, J. Singhal, S. Kulkarni, S. Horton, C. Tait, D. Mehta, J. (1997). Total therapy of acute myeloid leukemia: 7-year follow-up. Blood, Vol.90 (10), pp. 1000-1000.

Powles, R. Kulkarni, S. Mehta, J. Treleaven, J. Millar, B. Shepherd, V. Tait, D. Antrum, J. Neville, F. Long, S. Rowland, A. Singhal, S. (1997). A double-blind randomized study comparing the efficacy of allogeneic marrow versus blood stem cell transplantation. Blood, Vol.90 (10), pp. 1118-1118.

Mateos, P. Lafuente, A. Rodriguez, M. Kulkarni, S. Mehta, J. Singhal, S. Saso, R. Gregory, K. Dark, G. Tait, D. Treleaven, J. Powles, R. (1997). Hepatic veno-occlusive disease (VOD) treated with recombinant tissue plasminogen activator (rt-PA). Blood, Vol.90 (10), pp. 964-964.

Moody, A.M. Norman, A.R. Tait, D. (1996). Paediatric tumours in the adult population: the experience of the Royal Marsden Hospital 1974-1990. Med pediatr oncol, Vol.26 (3), pp. 153-159. show abstract

Huddart, R.A. Nahum, A. Neal, A. McLean, M. Dearnaley, D.P. Law, M. Dyer, J. Tait, D. (1996). Accuracy of pelvic radiotherapy: prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy. Radiother oncol, Vol.39 (1), pp. 19-29. show abstract

The aim of this study was to assess the accuracy of pelvic radiotherapy during a trial of blocked radiotherapy at the Royal Marsden Hospital, UK. Prospective evaluation was performed on 90 patients receiving CT planned pelvic radiotherapy using weekly anterior-posterior and lateral portal films. Field placement errors (FPEs) were calculated by comparing field centres of each film with a designated point of interest. Data was evaluated to calculate the overall treatment simulator differences, the number of error free treatments, and mean treatment-simulator position and to evaluate the role of systematic versus random errors. Age, weight, disease site, position of treatment, fractionation, blocked versus conventional techniques were assessed for their effect on treatment accuracy. The mean absolute error between treatment and simulator films was anterior right-left (ARL) 0.25 cm, anterior superior-inferior (ASI) 0.32 cm, lateral anterior-posterior (LAP) 0.42 cm, and lateral superior-inferior (LSI) 0.28 cm. On average the field centre was displaced by 0.66 cm (standard deviation, S.D. = 0.34) from that intended. On each treatment day 29% of anterior films and 45% of lateral films had at least one 0.5 cm error. Overall 59% of treatments had at least one 0.5 cm error and 9% a 1.0 cm error. The field centre was more than 0.5 cm from the position intended in 66% of treatments and over 1 cm for 14% of treatments. Analysis of variance showed that both random and systematic errors occurred in all directions. Though random errors were of similar magnitude in all direction (variance sigma 2 = 0.06-0.09 cm2); systematic errors showed a 4-fold variation being greatest in the LAP direction (sigma 2 = 0.19 cm2) and least the ARL direction (sigma 2 = 0.048 cm2). No factor consistently predicted for worse outcome in all directions. Hypofractionated treatments were less accurate in the LSI direction (P > 0.05). Systematic errors were associated in the ARL direction with hypofractionation (P < 0.01) and, in the LSI direction with weight (P < 0.03) and age (P < 0.05). We conclude that significant random and systematic errors can occur during pelvic radiotherapy especially in the LAP direction. These results suggest that in the absence of a customised immobilisation device, to cover 95% of errors, margins of 0.6 cm for RL and SI directions and 0.9 cm for AP direction should be allowed between the planning and clinical target volumes. However, ideally, each centre should determine their own margin requirements according to local clinical practice..

Singhal, S. Powles, R. Treleaven, J. Horton, C. Tait, D. Meller, S. Pinkerton, C.R. Mehta, J. (1996). Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. Bone marrow transplant, Vol.17 (4), pp. 637-641. show abstract

Tait, D. (1996). Oncology and the BJR - Commentary. British journal of radiology, Vol.69 (820), pp. 293-293.

Mehta, J. Powles, R. Singhal, S. Horton, C. Tait, D. Treleaven, J. (1996). Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission. Bone marrow transplant, Vol.18 (1), pp. 119-123. show abstract

Mehta, J. Powles, R. Treleaven, J. Horton, C. Tait, D. Meller, S. Pinkerton, C.R. Middleton, G. Eisen, T. Singhal, S. (1996). Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone marrow transplant, Vol.18 (4), pp. 741-746. show abstract

Tanner, S.F. Clarke, J. Leach, M.O. Mesbahi, M.H. Nicolson, V. Powles, R. Husband, J.E. Tait, D. (1996). MRI in the evaluation of late bone marrow changes following bone marrow transplantation. Br j radiol, Vol.69 (828), pp. 1145-1151. show abstract

Wilson, K. Powles, R. Treleaven, J. Singhal, S. Horton, C. Tait, D. Kulkarni, S. Saso, R. Alton, P. Killick, S. Mehta, J. (1996). Allografting after melphalan total body irradiation for first remission acute myeloid leukemia. Blood, Vol.88 (10), pp. 2441-2441.

Singhal, S. Powles, R. Treleaven, J. Kulkarni, S. Horton, C. Tait, D. Mehta, J. (1996). Sequential high-dose therapy of adult acute lymphoblastic leukemia: Blood cell autografts with maintenance therapy in first remission and allografting in second remission for relapsing patients. Blood, Vol.88 (10), pp. 490-490.

Glynne, P. Powles, R. Steele, J. Singhal, S. Treleaven, J. Tait, D. Mehta, J. (1996). Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia. Acta oncol, Vol.35 (6), pp. 709-712. show abstract

Mehta, J. Powles, R. Singhal, S. Tait, D. Swansbury, J. Treleaven, J. (1995). Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone marrow transplant, Vol.16 (1), pp. 133-137. show abstract

Powles, R. Mehta, J. Singhal, S. Horton, C. Tait, D. Milan, S. Pollard, C. Lumley, H. Matthey, F. Shirley, J. (1995). Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Bone marrow transplant, Vol.16 (2), pp. 241-247. show abstract

Mehta, J. Powles, R. Singhal, S. Horton, C. Tait, D. Milan, S. Meller, S. Pinkerton, C.R. Treleaven, J. (1995). Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone marrow transplant, Vol.16 (4), pp. 499-506. show abstract

Whitton, A.C. Syndikus, I. Tait, D.M. Bloom, H.J. (1995). Radiotherapy and adjuvant chemotherapy for childhood medulloblastoma The Royal Marsden Hospital experience. Strahlenther onkol, Vol.171 (11), pp. 615-621. show abstract

Mehta, J. Powles, R. Singhal, S. Tait, D. Hjiyiannakis, P. Prendiville, J. Glynne, P. Horton, C. Treleaven, J. (1995). Allogeneic bone marrow transplantation for acute myeloid leukemia after melphalan and total body irradiation. European journal of cancer, Vol.31A, pp. 1130-1130.

Mehta, J. Singhal, S. Treleaven, J. Horton, C. Tait, D. Powles, R. (1995). Long-term follow-up of allogeneic marrow transplantation for acute myeloid leukemia after cyclophosphamide total body irradiation and cyclosporine. European journal of cancer, Vol.31A, pp. 1129-1129.

Treleaven, J. Powles, R. Singhal, S. Horton, C. Tait, D. Meller, S. Pinkerton, C.R. Mehta, J. (1995). Melphalan and total-body irradiation as a conditioning regimen for autologous bone marrow transplantation in acute myeloid leukemia. Blood, Vol.86 (10), pp. 3861-3861.

Mehta, J. Powles, R. Singhal, S. Horton, C. Tait, D. Treleaven, J. (1995). Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and cyclosporine: Long-term follow-up. Blood, Vol.86 (10), pp. 360-360.

Davidson, A. Childs, J. Hopewell, J.W. Tait, D. (1994). Functional neurological outcome in leukaemic children receiving repeated cranial irradiation. Radiother oncol, Vol.31 (2), pp. 101-109. show abstract

Burnet, N.G. Wurm, R. Tait, D.M. Peacock, J.H. (1994). Cellular sensitivity and low dose-rate recovery in Fanconi anaemia fibroblasts. Br j radiol, Vol.67 (798), pp. 579-583. show abstract

Mehta, J. Powles, R. Horton, C. Milan, S. Treleaven, J. Tait, D. Catovsky, D. (1994). Bone marrow transplantation for primary refractory acute leukaemia. Bone marrow transplant, Vol.14 (3), pp. 415-418. show abstract

Fife, K. Milan, S. Westbrook, K. Powles, R. Tait, D. (1994). Risk factors for requiring cataract surgery following total body irradiation. Radiother oncol, Vol.33 (2), pp. 93-98. show abstract

MEHTA, J. POWLES, R. TRELEAVEN, J. SINGHAL, S. HORTON, C. TAIT, D. MILAN, S. MELLER, S. PINKERTON, C.R. CHANG, J. HAMBLIN, M. ODRISCOLL, A. ZOMAS, A. CATOVSKY, D. (1994). MELPHALAN VERSUS CYCLOPHOSPHAMIDE WITH TOTAL-BODY IRRADIATION AS CONDITIONING FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION IN 1ST REMISSION ACUTE MYELOID-LEUKEMIA. Blood, Vol.84 (10), pp. A714-A714.

POWLES, R. MEHTA, J. SINGHAL, S. TRELEAVEN, J. HORTON, C. TAIT, D. MILAN, S. MELLER, S. PINKERTON, C.R. CATOVSKY, D. (1994). AUTOGRAFTING FOR ACUTE MYELOID-LEUKEMIA IN 1ST REMISSION - EVALUATION OF A CONDITIONING REGIMEN CONTAINING MELPHALAN AND IDENTIFICATION OF MODIFIABLE TREATMENT-RELATED PROGNOSTIC FACTORS. Blood, Vol.84 (10), pp. A718-A718.

Syndikus, I. Tait, D. Ashley, S. Jannoun, L. (1994). Long-term follow-up of young children with brain tumors after irradiation. Int j radiat oncol biol phys, Vol.30 (4), pp. 781-787. show abstract

Tait, D.M. (1993). Pediatric radiotherapy. Curr opin pediatr, Vol.5 (1), pp. 117-123. show abstract

Ryalls, M. Spoudeas, H.A. Hindmarsh, P.C. Matthews, D.R. Tait, D.M. Meller, S.T. Brook, C.G. (1993). Short-term endocrine consequences of total body irradiation and bone marrow transplantation in children treated for leukemia. J endocrinol, Vol.136 (2), pp. 331-338. show abstract

Eeles, R.A. Warren, W. Knee, G. Bartek, J. Averill, D. Stratton, M.R. Blake, P.R. Tait, D.M. Lane, D.P. Easton, D.F. (1993). Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene, Vol.8 (5), pp. 1269-1276. show abstract

Tait, D.M. Nahum, A.E. Rigby, L. Chow, M. Mayles, W.P. Dearnaley, D.P. Horwich, A. (1993). Conformal radiotherapy of the pelvis: assessment of acute toxicity. Radiother oncol, Vol.29 (2), pp. 117-126. show abstract

Mayles, W.P. Chow, M. Dyer, J. Fernandez, E.M. Heisig, S. Knight, R.T. Moore, I. Nahum, A.E. Shentall, G.S. Tait, D.M. (1993). The Royal Marsden Hospital pelvic radiotherapy trial: technical aspects and quality assurance. Radiother oncol, Vol.29 (2), pp. 184-191. show abstract

Tait, D.M. Eeles, R.A. Carter, R. Ashley, S. Ormerod, M.G. (1993). Ploidy and proliferative index in medulloblastoma: useful prognostic factors?. Eur j cancer, Vol.29A (10), pp. 1383-1387. show abstract

O'Brien, M.E. Pinkerton, C.R. Kingston, J. Mott, M. Tait, D. Meller, S. Radford, M. Malpas, J. McElwain, T.J. (1992). 'VEEP' in children with Hodgkin's disease--a regimen to decrease late sequelae. Br j cancer, Vol.65 (5), pp. 756-760. show abstract full text

Tiley, C. Powles, R. Catalano, J. Treleaven, J. Eshelby, J. Hewetson, M. Tait, D. Cunningham, D. (1992). Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk lymphoma, Vol.7 (4), pp. 317-321. show abstract

Ott, R.J. Tait, D. Flower, M.A. Babich, J.W. Lambrecht, R.M. (1992). Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br j radiol, Vol.65 (777), pp. 787-791. show abstract

Hoskin, P.J. Rajan, B. Ebbs, S. Tait, D. Milan, S. Yarnold, J.R. (1992). Selective avoidance of lymphatic radiotherapy in the conservative management of early breast cancer. Radiother oncol, Vol.25 (2), pp. 83-88. show abstract

BALL, A.B. TAIT, D.M. FISHER, C. SINNETT, H.D. HARMER, C.L. (1991). TREATMENT OF METASTATIC PARAAORTIC PARAGANGLIOMA BY SURGERY, RADIOTHERAPY AND I-131 METAIODOBENZYLGUANIDINE. European journal of surgical oncology, Vol.17 (5), pp. 543-4.

SCHROEDER, H. PINKERTON, C.R. POWLES, R.L. MELLER, S.T. TAIT, D. MILAN, S. MCELWAIN, T.J. (1991). HIGH-DOSE MELPHALAN AND TOTAL-BODY IRRADIATION WITH AUTOLOGOUS MARROW RESCUE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA AFTER RELAPSE. Bone marrow transplantation, Vol.7 (1), pp. 11-15.

Pinkerton, C.R. Groot-Loonen, J. Barrett, A. Meller, S.T. Tait, D. Ashley, S. McElwain, T.J. (1991). Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. Br j cancer, Vol.64 (2), pp. 381-385. show abstract full text

Ball, A.B. Tait, D.M. Fisher, C. Sinnett, H.D. Harmer, C.L. (1991). Treatment of metastatic para-aortic paraganglioma by surgery, radiotherapy and I-131 mIBG. Eur j surg oncol, Vol.17 (5), pp. 543-546. show abstract

Corbett, R. Pinkerton, R. Tait, D. Meller, S. (1991). [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J nucl biol med (1991), Vol.35 (4), pp. 228-231. show abstract

Tait, D.M. Thornton-Jones, H. Bloom, H.J. Lemerle, J. Morris-Jones, P. (1990). Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur j cancer, Vol.26 (4), pp. 464-469. show abstract

TAIT, D. (1990). CONFORMAL THERAPY. British journal of cancer, Vol.62 (5), pp. 702-704.

TAIT, D. (1990). SYSTEMIC RADIOTHERAPY. European journal of nuclear medicine, Vol.17 (5), pp. 201-202.

Tait, D.M. Nahum, A.E. (1990). Conformal therapy. Eur j cancer, Vol.26 (6), pp. 750-753.

Rowell, N.P. McCready, V.R. Tait, D. Flower, M.A. Cronin, B. Adams, G.E. Horwich, A. (1989). Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. Br j cancer, Vol.59 (1), pp. 135-141. show abstract full text

ROWELL, N.P. MCCREADY, V.R. TAIT, D. FLOWER, M.A. CRONIN, B. HORWICH, A. (1988). TECHNETIUM-99M HMPAO SPECT AND BLOOD-FLOW PATTERNS IN HUMAN-LUNG TUMORS. British journal of cancer, Vol.58 (4), pp. 533-1.

MCCREADY, V.R. BABICH, J. FLOWER, M.A. HAMMERSLEY, P.A. OTT, R. TAIT, D. (1988). THE USE OF TC-99M-HMPAO FOR TUMOR-DETECTION AND THE STUDY OF TUMOR BLOOD-FLOW. Nuklearmedizin, Vol.27 (3), pp. 116-117.

Tait, D. Nahum, A. Southall, C. Chow, M. Yarnold, J.R. (1988). Benefits expected from simple conformal radiotherapy in the treatment of pelvic tumours. Radiother oncol, Vol.13 (1), pp. 23-30. show abstract

TAIT, D. NAHUM, A. SOUTHALL, C. YARNOLD, J.R. (1987). BENEFITS EXPECTED FROM CONFORMATION RADIOTHERAPY IN THE TREATMENT OF PELVIC TUMORS. British journal of cancer, Vol.56 (6), pp. 868-1.

Tait, D. McCready, V.R. Ott, R.J. (1987). HM-PAO assessment of human tumour perfusion. Eur j cancer clin oncol, Vol.23 (6), pp. 789-793. show abstract

TAIT, D.M. CARNOCHAN, P. (1987). THERMAL ENHANCEMENT OF RADIATION RESPONSE - A GROWTH DELAY STUDY ON SUPERFICIAL HUMAN-TUMOR METASTASES. Radiotherapy and oncology, Vol.9 (3), pp. 231-240.

CARNOCHAN, P. TAIT, D. MAHER, J. (1987). LOCALIZED HYPERTHERMIA IN SUPERFICIAL LESIONS - A SUMMARY OF HEATING-SYSTEM PERFORMANCE. International journal of hyperthermia, Vol.3 (6), pp. 555-555.

MAUREEMOOTOO, K. TAIT, D. CARNOCHAN, P. MCGOVERN, C. (1986). THE EVALUATION OF A XENON CLEARANCE TECHNIQUE FOR THE QUANTIFICATION OF VASCULAR CHANGES INDUCED BY HYPERTHERMIA IN HUMAN-TUMORS. Physics in medicine and biology, Vol.31 (3), pp. 314-314.

EELES, R. TAIT, D.M. PECKHAM, M.J. (1986). LHERMITTE SIGN AS A COMPLICATION OF CISPLATIN-CONTAINING CHEMOTHERAPY FOR TESTICULAR CANCER. Cancer treatment reports, Vol.70 (7), pp. 905-3.

TAIT, D.M. GOLDSTRAW, P. HUSBAND, J.E. (1986). THYMIC REBOUND IN AN ADULT FOLLOWING CHEMOTHERAPY FOR TESTICULAR CANCER. European journal of surgical oncology, Vol.12 (4), pp. 385-387.

TAIT, D. CARNOCHAN, P. (1985). QUANTITATIVE STUDY OF THE EFFECT OF HYPERTHERMIA IN ADDITION TO SINGLE DOSES OF RADIOTHERAPY IN PATIENTS WITH MULTIPLE SUPERFICIAL METASTASES. Strahlentherapie, Vol.161 (9), pp. 551-551.

CARNOCHAN, P. TAIT, D. (1985). A THERMAL METHOD FOR THE STUDY OF BLOOD-FLOW CHANGES DURING CLINICAL HYPERTHERMIA. Strahlentherapie, Vol.161 (9), pp. 526-526.

TAIT, D. PECKHAM, M.J. HENDRY, W.F. GOLDSTRAW, P. (1984). POST-CHEMOTHERAPY SURGERY IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR-TUMORS - THE SIGNIFICANCE OF HISTOLOGY WITH PARTICULAR REFERENCE TO DIFFERENTIATED (MATURE) TERATOMA. British journal of cancer, Vol.50 (5), pp. 601-609. full text

Types of Publications

Journal Articles

Book Chapters

Conferences

In this section